financetom
Business
financetom
/
Business
/
Roper Technologies Q2 Adjusted Earnings, Revenue Rise; Updates 2024 Earnings Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Roper Technologies Q2 Adjusted Earnings, Revenue Rise; Updates 2024 Earnings Outlook
Jul 24, 2024 4:55 AM

07:27 AM EDT, 07/24/2024 (MT Newswires) -- Roper Technologies ( ROP ) reported Q2 adjusted earnings Wednesday of $4.48 per diluted share, up from $4.12 a year earlier.

Analysts polled by Capital IQ expected $4.47.

Revenue for the quarter ended June 30 was $1.72 billion, compared with $1.53 billion a year earlier.

Analysts surveyed by Capital IQ expected $1.73 billion.

The company updated its full-year 2024 adjusted EPS guidance to now be $18.10 to $18.25 from the prior outlook of $18.05 to $18.25. Analysts surveyed by Capital IQ expect $18.20. The company reiterated its annual revenue growth outlook at about 12%. Analysts polled by Capital IQ expect $6.92 billion.

For Q3, the company expects adjusted EPS of $4.50 to $4.54. Analysts surveyed by Capital IQ expect $4.62.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Pfizer's Paxlovid fails as 15-day treatment for long COVID, study finds
Pfizer's Paxlovid fails as 15-day treatment for long COVID, study finds
Jun 7, 2024
(Reuters) - A 15-day course of Pfizer's ( PFE ) COVID-19 antiviral treatment Paxlovid did not relieve symptoms of long COVID, according a study by Stanford University researchers. Currently, there are no proven treatments specifically for long COVID in which a host of symptoms can last for many months after initial coronavirus infection. Scientists and patients had hoped that Pfizer's...
Arcturus Therapeutics Prospective Cystic Fibrosis Treatment Shows Positive Results -- Shares Tumble
Arcturus Therapeutics Prospective Cystic Fibrosis Treatment Shows Positive Results -- Shares Tumble
Jun 7, 2024
03:16 PM EDT, 06/07/2024 (MT Newswires) -- Arcturus Therapeutics ( ARCT ) slumped more than 29% in Friday trading, despite reporting positive preliminary data from phase 1 and phase 1b study of its ARCT-032 prospective treatment for cystic fibrosis. Appearing at an industry conference in Glasgow, Scotland, executives of the the messenger RNA medicines and vaccines company said the inhaled...
US State Dept OKs potential sale of missiles to Denmark, Pentagon says
US State Dept OKs potential sale of missiles to Denmark, Pentagon says
Jun 7, 2024
WASHINGTON, June 7 (Reuters) - The U.S. State Department has approved the potential sale of advanced medium-range air-to-air missiles and related equipment to Denmark for an estimated cost of $215.5 million, the Pentagon said on Friday. Denmark has asked to buy 84 AIM-120C-8 Advanced Medium-Range Air-to-Air Missiles and three AIM-120 AMRAAM guidance sections, the Pentagon said. The principal contractor will...
Copper output from Chile's Codelco down 6% in April
Copper output from Chile's Codelco down 6% in April
Jun 7, 2024
SANTIAGO, June 7 (Reuters) - Copper production from Chile's state-run miner Codelco, the world's largest producer of the metal, dropped 6.1% in April compared to the same month last year to total 95,100 metric tons, data from copper commission Cochilco showed on Friday. Copper output also fell during the month at Chile's Escondida mine, though it edged up 1.9% in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved